Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

PHASE2CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Hyperlipidemia
Interventions
DRUG

Placebo

2 capsules, once a day for 8 weeks

DRUG

MBX-8025

2 capsules, once daily for 8 weeks

DRUG

MBX-8025

2 capsule, once daily for 8 weeks

DRUG

Atorvastatin

2 capsules, once daily for 8 weeks

DRUG

MBX-8025

2 capsules, once daily for 8 weeks

DRUG

MBX-8025

2 capsules, once daily for 8 weeks

Trial Locations (28)

13901

United Medical Associates P.C., Binghamton

14224

Southgate Medical Group, West Seneca

14609

Rochester Clinical Research, Rochester

14787

Great Lakes Medical Research, Westfield

19146

PHA-Adult Medicine, Philadelphia

21209

Health Trends Research LLC, Baltimore

27103

Piedmont Medical Research Associates, Winston-Salem

27401

PharmQuest, Greensboro

28144

Crescent Medical Research, Salisbury

29651

Radiant Research, Greer

35209

Radiant Research, Birmingham

37620

Tricities Medical Research, Bristol

37660

Holston Medical Group Clinical Research, Kingsport

40213

L-Marc Research Center, Louisville

46260

Genesis Research International, Indianapolis

Midwest Institute for Clinical Research Inc., Indianapolis

Maine Research Associates, Auburn

48098

Troy Internal Medicine Research, Troy

75230

Dallas Diabetes and Endocrine Center, Dallas

78229

Diabetes and Glandular Disease Research, San Antonio

85032

Anasazi Internal Medicine Research, Phoenix

87108

Rochester Clinical Research, Albuquerque

92648

Diabetes/Lipid Management and Research Center, Huntington Beach

95405

Radiant Research, Santa Rosa

99362

Walla Walla Clinic, Walla Walla

06460

Clinical Research Consulting LLC, Milford

08807

Bridgewater Medical Group, Bridgewater

07013

Clifton-Wallington Medical Group, Clifton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY